Navigation Links
Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
Date:7/31/2008

BASINGSTOKE, England and PHILADELPHIA, July 31 /PRNewswire-FirstCall/ -- Shire Limited (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company announces results for the three months to June 30, 2008.
Q2 2008 Financial Highlights

- Product sales up 40% to $706m

- Product sales excluding ADDERALL XR(R) up 64% to $409m

- New product sales(1) $243m, 34% of product sales (2007: 18%)

- Total revenues up 35% to $776m

- US GAAP earnings per ADS: loss $0.44 (2007: loss $9.93)

- Non GAAP earnings per ADS up 70% to $0.95 (2007: $0.56)

- Revenue guidance upgraded - 2008 revenue growth now expected to

be at least 20% (previous guidance: mid to high teens)

(1) New product sales comprise DAYTRANA, ELAPRASE, FOSRENOL, LIALDA /

MEZAVANT and VYVANSE

Angus Russell, Chief Executive Officer, commented:

"Shire continues to deliver strong growth and broaden its business in specialty biopharmaceuticals. Our product sales for the quarter were up 40% on Q2 2007 with sales of new products now comprising 34% of total product sales. At $409m, product sales excluding ADDERALL XR were up 64% reflecting the success of our strategy to build a pipeline and portfolio for Shire's future growth.

"We are pleased with the performance of ELAPRASE, FOSRENOL, LIALDA, REPLAGAL and VYVANSE and are looking forward to the continued growth of VYVANSE in the US supplemented by the recent launch of the adult indication, the additional dosage strengths and the back-to-school season.

"We have decided to commence a phased discontinuation of DYNEPO. Resources supporting this product will be re-directed to faster growing, profitable core global products.

"The proposed acquisition of Jerini AG in Germany, which we expect to complete in Q3, is an excellent match for our business and we expect to benefit from both its near term revenues and long term growth. The recent EU approval of Je
'/>"/>

SOURCE Shire Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...ave an opportunity to take the lead in two small b...ity of Valencia (UV), working together with the ID...ic of the Spanish biotechnology industry. Their co...ve more clout than those in English-speaking count...nts has been overlooked by the leading countries i...
(Date:11/20/2009)...swire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) ...nth Circuit Court of Appeals reversed a U.S. Distr...ed to pursue all of its claims against The Lash Gr...or trial. CTI filed a complaint against The Lash ...ultant for CTI,s product TRISENOX, in 2007 seeking...
(Date:11/19/2009)...e-FirstCall/ -- Omeros Corporation (Nasdaq: OMER ...the third quarter ended September 30, 2009. For th...ported a net loss of $3.9 million, or $1.34 per sh... $2.54 per share, for the same period in 2008. For...pany reported a net loss of $15.5 million, or $5.2...
(Date:11/19/2009)...M, Mass., Nov. 19 Arlington Medica... the leading driver of antibiotic selection in nos...vity against gram-positive and gram-negative patho...se nosocomial pneumonia, surveyed European physici...t provide appropriate coverage against common path...
Breaking Biology Technology:Spanish biotechnology should focus on food and plant sectors to be more competitive 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3
...ternatives to Protect Privacy and Advance,Healthca...Health Insurance Portability and Accountability Ac...ce of biomedical research and the search for,treat...report by the,Association of Academic Health Cente... Discovery describes the unintended disruptive con...
...he Endocrine Society, an,international association..., today hosted a teleconference for security analy...conference of the Society, which is now,being held...bers from 80,countries, many of whom attend the co...rine research and clinical care., The purpose of ...
...non-profit on path to cure diabetes, MINNEAPOLIS,...ofit organization created to expedite the widespre... has attracted two well-known experts to its,Board...Clark., (Logo: http://www.newscom.com/cgi-bin/pr...chief executive officer for the National Pork,Boar...
Other Biology Technology:HIPAA Privacy Rule Impedes Biomedical Research 2'Breakthroughs Ahead,' Endocrine Society Tells Security Analysts 2Spring Point Project Names New Members to Board of Directors 2
(Date:11/19/2009)...Leaf-cutter ants, which cultivate fungus for food,... one to add to the list: the ant farmers, like the...acteria to make their gardens grow. The finding, r...e , documents a previously unknown symbiosis betwe... leaf-cutter ants have come to dominate the Americ...
(Date:11/19/2009)...omes to corn, 1 + 1 = more than 2: The offspring o...f their parents. Characterizing the gene-level var...eterosis or hybrid vigor, could boost our ability ...s high protein content for human consumption or hi...p from the newly released DNA sequence of the comm...
(Date:11/19/2009)..., WALL, N.J., Nov. 19 ...KYI), a leader in wireless public safety and finge...ced that the Special Shareholder Meeting held toda...ause a quorum was not present. ,, (Logo: http:...) ,, While an impressive 99.3% of the 35 millio...
Breaking Biology News(10 mins):Like humans, ants use bacteria to make their gardens grow 2U of M plant scientist uncovers clues to yield-boosting quirks of corn genome 2BIO-key(R) Provides Update to Special Shareholder Meeting 2BIO-key(R) Provides Update to Special Shareholder Meeting 3Dual Frost 26 Sullivan Accolade for Veolia Water Solutions 26 Technologies 50844 1Dual Frost 26 Sullivan Accolade for Veolia Water Solutions 26 Technologies 50844 2Dual Frost 26 Sullivan Accolade for Veolia Water Solutions 26 Technologies 50844 3Dual Frost 26 Sullivan Accolade for Veolia Water Solutions 26 Technologies 50844 4Dual Frost 26 Sullivan Accolade for Veolia Water Solutions 26 Technologies 50844 5MRI accurately depicts deep endometriosis 50842 1MRI accurately depicts deep endometriosis 50842 2Finding the constant in bacterial communication 9128 1Finding the constant in bacterial communication 9128 2Finding the constant in bacterial communication 9128 3
...Many of the areas of the human genome previously t..., a scientist will tell the annual conference of t...ay 19 June). , Most known human genes in the genom...ssor Alexandre Reymond, from the Centre for Integr...d and the Department of Genetic Medicine, Universi...
...neers at Duke,s Pratt School of Engineering have a... might guide minimally invasive brain surgeries an...tion. , The “brain scope,” which is inserted into...ly useful for the bedside evaluation of critically...gnetic resonance imaging (MRI) equipment is unavai...
... has identified a new biological function for a so... the ability to block allergic response, setting t...allergy. , Allergic disease is the sixth leading c...while various treatments have been developed to co...ngs advance the emerging field of medicine known a...
Other Biology News:Human genetic 'deserts' are teeming with significant life 23-D ultrasound scanner provides in-depth view of the brain 2Researchers develop buckyballs to fight allergy 2
...ty Laboratory Osmometer for both 0.2 and 2.0 mL sa... built-in printer, keypad, and software for statis...ng capability with optional scanner. RS-232 port. ...tep Calibration. ...
Secure-Seal™ hybridization chamber gasket, eight chambers, 9 mm diameter, 0.8 mm deep *set of 20* from Molecular Probes (Invitrogen)
Rabbit Anti-Human SCNN1A Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Rat Anti-Mouse F4 / 80 Antigen Monoclonal Antibody, Biotin Conjugated from AbD Serotec
Biology Products: